Population pharmacokinetic analysis of rivaroxaban in healthy volunteers and patients with radiofrequency ablation of non-valvular atrial fibrillation in China
The PopPK model of rivaroxaban in healthy volunteers and patients with NVAF developed in this study was expected to help provide relevant PK parameters and covariate information for further studies of rivaroxaban. The study indicated that a daily dose of 15 mg may be appropriate as the primary dosage of rivaroxaban for Chinese patients with NVAF. A lower dose is recommended for patients with moderate renal impairment to avoid overexposure.
Authors
- Yu Xiang (ORCID: https://orcid.org/0000-0002-7521-0374)
- Mingsheng Hu (ORCID: https://orcid.org/0000-0002-7220-1456)
- Yingrong Chen (ORCID: https://orcid.org/0000-0003-2901-0600)
- Mengli Tian
- Junlong Sun (ORCID: https://orcid.org/0000-0001-7722-0018)
- Chen Zhang (ORCID: https://orcid.org/0000-0002-8198-3090)
- Fangfang Gu
- Cong Zhang (ORCID: https://orcid.org/0009-0000-2409-2147)
- Kaixian Tang
Institutions
- Huzhou Central Hospital (CN)
- Community Health Center (US)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-05-29
- DOI
- https://doi.org/10.3389/fphar.2025.1562259
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Medical Science and Technology Project of Zhejiang Province